Latest Licensing News

Arafura Rare Earths has locked in binding cornerstone equity agreements worth approximately A$230 million, bolstering its path to a final investment decision for the Nolans Project. The company also acquired critical camp infrastructure and is progressing technology development and offtake negotiations amid supportive government frameworks.

Asian Battery Metals has completed its acquisition of the Maikhan Uul Cu-Au VMS Project and is poised to start a fully permitted 2026 drilling campaign across its Mongolian copper and battery metals assets, backed by $5.25 million in cash.

Sovereign Metals' March 2026 update reveals a robust DFS for its Kasiya Rutile-Graphite Project, a substantial resource upgrade, strategic offtake MOUs, and a high-value heavy rare earth by-product discovery.

EVE Health Group has begun commercial sales of Libbo, an oral dissolving film for erectile dysfunction, supported by a new digital men’s health platform. The company also expanded its pharmaceutical pipeline and secured $1.3 million in fresh capital to fund ongoing development and commercialization.

Argosy Minerals pushes forward its 12ktpa Rincon Lithium Project in Argentina, nearing DFS completion and securing a key 40MW energy infrastructure agreement amid robust lithium market demand.

TG Metals has expanded its Van Uden gold resource to 270,800 ounces with a 120% increase in indicated ounces, discovered new mineralisation 550m south, and filed a lithium processing patent at Lake Johnston.

Red Sky Energy bolsters its Innamincka Dome operations with binding AFEs for new wells and a $5.2 million capital raise, targeting near-term production growth and cashflow.

Acrux pivots from generics to developing a Female Testosterone therapy for HSDD, leveraging FDA feedback and a strong US market opportunity.

Atomo Diagnostics capitalises on Lumos Diagnostics’ FebriDx FDA CLIA waiver with over $2 million in new sales orders and a $3 million capital raise, expanding its global footprint and product pipeline.

Dimerix’s blinded review of its pivotal ACTION3 Phase 3 trial confirms over 90% statistical power to detect DMX-200’s effect on proteinuria, reinforcing the study’s design and regulatory pathway.

Cambium Bio has clinched FDA agreement on a streamlined single pivotal Phase 3 trial for Elate Ocular®, cutting development complexity, while bolstering its cash position through a A$2.4 million strategic placement by major shareholder ZYBT.

INOVIQ Limited is on track to complete its EXO-OC™ ovarian cancer screening study by mid-2026 and is accelerating its CAR-exosome therapy program, supported by a strong cash position of A$11.9 million.